Tilray Surges Then Plunges on Cannabis Rescheduling News — The Policy Trade Trap

Tilray spiked then sharply reversed after the DOJ announced rescheduling medical cannabis to Schedule 3. Once investors realized the move was limited to medical use — not full adult-use legalization — most of the gains were erased.

Daniel Kim·April 24, 2026·5 min read

AI Summary

Tilray surged then sharply reversed after the DOJ announced it would reschedule medical cannabis to Schedule 3. The rally faded once investors confirmed the measure is limited to medical use and does not constitute broader adult-use legalization. With a $300 million pharmaceutical distribution platform and established medical cannabis infrastructure, Tilray is better positioned to benefit than pure-play speculative names. Fundamentals continue to improve, with Q2 FY2026 net revenue reaching a record $217.5 million.

DOJ Reschedules Medical Cannabis to Schedule 3 Only — Full Adult-Use Legalization Not on the Table

Cannabis-related stocks, including Tilray Brands (TLRY), surged in pre-market trading after the U.S. Department of Justice announced plans to reschedule FDA-approved, state-licensed medical cannabis products from Schedule 1 to Schedule 3. However, most of those gains were reversed once the actual scope of the policy change became clear.

The critical distinction: this is not a nationwide cannabis legalization. The rescheduling applies exclusively to FDA-approved, state-licensed medical cannabis products and does not extend to the adult-use recreational market. The DEA's formal rulemaking process remains ongoing, with hearings having been delayed again past January 2025. It was a textbook "policy trade cooldown" — markets reacted to the headline, then pulled back after digesting the details.

Tilray's Medical Cannabis Platform Positions It as a Primary Beneficiary

Analysts suggest Tilray stands to benefit more from this policy shift than most cannabis peers. The company already operates Tilray Medical U.S., a global medical cannabis division generating approximately $150 million in annual revenue, alongside Tilray Pharma, a pharmaceutical distribution platform valued at roughly $300 million. Management has indicated it intends to leverage the rescheduling as a catalyst for expanding medical cannabis research in the U.S., improving patient access, and accelerating new product development.

Fundamentals are also trending in the right direction. Net revenue for Q2 FY2026 hit a record $217.5 million, with international medical cannabis sales climbing 36% year-over-year. Tilray Pharma posted a quarterly record of $85.3 million in revenue. The company holds $291.6 million in cash and liquid assets and has successfully transitioned to a net cash position of $27.4 million. Adjusted EBITDA guidance for FY2026 stands at $62 million to $72 million.

"The Stock Moved Faster Than the Policy"

The lesson here is straightforward. In the cannabis sector, policy headlines move share prices quickly — but the actual commercial impact materializes far more slowly. While this rescheduling is a net positive for medical cannabis operators — improving research access and potentially easing certain tax burdens — meaningful effects on the income statement will require additional regulatory steps and time. In Tilray's case, its diversified business model spanning medical cannabis, beverages, wellness, and pharmaceutical distribution provides a more stable floor than pure-play cannabis speculative names.

Data Reference

Based on the U.S. Department of Justice Schedule 3 rescheduling announcement and Tilray Brands Q2 FY2026 earnings release. DEA formal rulemaking process is ongoing.

InteliView Editorial | April 24, 2026